Shrinking Back Rule

The Shrinking Back Rule is a regulatory mechanism that allows a taxpayer to isolate specific innovative components of a project for R&D credit eligibility when the project as a whole fails to meet the required experimental threshold. This provision ensures that qualifying research activities remain incentivized by applying the federal four-part test to smaller, discrete elements of a product or process rather than disqualifying the entire endeavor due to the presence of non-qualifying routine activities.

As research and development projects grow in complexity, particularly within New York’s burgeoning life sciences and high-technology sectors, the boundary between truly experimental activities and routine engineering becomes increasingly blurred. The Shrinking Back Rule serves as a critical interpretative tool, codified under Treasury Regulation Section 1.41-4(b)(2) and recognized by the New York State Department of Taxation and Finance through its conformity with federal Internal Revenue Code (IRC) Section 41. Without this rule, the “substantially all” requirement—which mandates that 80 percent or more of a business component’s activities must constitute a process of experimentation—would frequently lead to the disallowance of credits for large-scale projects where innovation is concentrated in specific sub-assemblies or software modules. By “shrinking” the definition of the business component down to the most significant subset of elements that satisfy the four-part test, the rule permits the preservation of qualified research expenses (QREs) that would otherwise be lost to the “all-or-nothing” nature of the overarching project analysis.

Theoretical Foundations: The Business Component and the Four-Part Test

To articulate the application of the Shrinking Back Rule, one must first delineate the standard for “qualified research” established under IRC Section 41(d). New York State, via the Excelsior Jobs Program and the Life Sciences Research and Development Tax Credit, largely adheres to these federal parameters. The law requires that for an activity to qualify for the credit, it must be related to a “business component,” defined as any product, process, computer software, technique, formula, or invention to be held for sale, lease, or license, or used by the taxpayer in its trade or business.

The qualification of these components is governed by the four-part test, a rigorous set of criteria designed to distinguish genuine innovation from routine commercial activity. The first criterion, the Section 174 Test, requires that the expenditures be eligible for treatment as expenses under Section 174 of the IRC, meaning they must represent research and development costs in the experimental or laboratory sense. This necessitates the existence of technical uncertainty at the outset of the project regarding the capability, method, or appropriate design of the component.

The second criterion mandates that the research be “Technological in Nature,” fundamentally relying on principles of the physical or biological sciences, engineering, or computer science. Third, the research must have a “Permitted Purpose,” specifically relating to a new or improved function, performance, reliability, or quality of the business component. Finally, “Substantially All” of the activities must constitute a “Process of Experimentation,” which involves a systematic evaluation of alternatives through modeling, simulation, or trial-and-error to resolve the identified technical uncertainties.

The “Substantially All” Threshold and the Necessity of Shrinking Back

The “substantially all” requirement is defined as 80 percent or more of the taxpayer’s research activities, measured on a cost or other consistently applied reasonable basis. In many sophisticated industrial applications, such as the development of a new medical device or a complex manufacturing line in upstate New York, the overall project often includes a substantial volume of work that does not meet the definition of a process of experimentation. This may include pre-production planning, tooling up for production, troubleshooting faults in existing equipment, or routine data accumulation.

If these non-qualified activities comprise more than 20 percent of the total project effort, the entire project fails the test at the highest business component level. The Shrinking Back Rule prevents the total loss of the credit by allowing the taxpayer to move down the hierarchy of the product. If the “airplane” fails as a business component, the taxpayer may shrink back to the “wing design.” If the wing design fails, they may shrink further to the “flap mechanism” or the “composite bonding technique”. This iterative refinement continues until a subset of elements is reached that satisfies the 80 percent threshold for experimentation.

Hierarchy Level	Example Component	Experimental Activity %	Qualification Status
Overall Project	Autonomous Delivery Drone	65%	Fails (does not meet 80%)
Major System	Navigation & Control System	75%	Fails (does not meet 80%)
Discrete Subset	Obstacle Avoidance Algorithm	95%	Qualifies via Shrinking Back
Discrete Subset	Battery Management Firmware	90%	Qualifies via Shrinking Back
Basic Element	Standard Rotors	0%	Fails (Routine Purchase)

New York State Statutory Context and Revenue Guidance

New York’s commitment to incentivizing innovation is evidenced by a suite of R&D-related tax credits, each of which incorporates the federal definitions of qualified research expenditures. The New York State Department of Taxation and Finance (DTF) and the Empire State Development (ESD) corporation provide the primary administrative oversight for these programs.

The Excelsior Jobs Program R&D Credit

The Excelsior Jobs Program (EJP) provides a refundable tax credit to businesses in strategic industries such as manufacturing, biotechnology, and software development. The R&D component of the EJP is particularly powerful, allowing taxpayers to claim up to 50 percent of the portion of their federal R&D credit that relates to expenditures conducted within New York State.

Guidance provided in TSB-M-11(6)I clarifies that the R&D credit component was increased significantly in 2011, moving from a 10 percent match to the current 50 percent match of the federal credit. This memorandum also notes that while the credit is generous, it is subject to a cap—generally 6 percent of the qualified New York expenditures, though this increases to 8 percent for “green” projects. For a taxpayer to utilize the Shrinking Back Rule under the Excelsior program, they must ensure that their federal credit (Form 6765) is properly substantiated at the component level, as the New York credit is derivative of the federal calculation.

The New York Life Sciences Research and Development Tax Credit

The Life Sciences R&D Tax Credit is specifically tailored to “new” life sciences businesses, emphasizing immediate liquidity for pre-revenue startups in fields like genomics, medical devices, and biopharmaceuticals. The credit rate is tiered based on the size of the entity: 20 percent for companies with fewer than 10 employees and 15 percent for those with 10 or more.

State guidance for this program emphasizes that QREs are restricted to wages and supplies, explicitly excluding contract research expenses, which differs from the federal treatment. This distinction makes the Shrinking Back Rule even more critical; because the pool of eligible expenses is narrower, taxpayers must be precise in isolating the specific in-house activities that meet the four-part test to ensure they reach the 80 percent threshold for the claimed components.

Technical Services Bureau Memoranda (TSB-M) and Tax Bulletins

New York’s revenue office has historically provided guidance that parallels federal standards for R&D. TSB-M-82(18)C, for instance, details the treatment of research and development property, highlighting that New York allows for special credit rates (such as the 7 percent investment tax credit rate for R&D property) and provides formulas for the recapture of such credits if the property ceases to be used in a qualified manner.

Further, Tax Bulletin TB-ST-773 provides a clear definition of “research and development in the experimental or laboratory sense” for sales tax purposes, which mirrors the Section 174 standards used for the income tax credit. The bulletin specifies that R&D includes advancing technology in a scientific field, developing new products, or improving existing ones. It explicitly excludes “ordinary testing or inspection of materials or products for quality control,” “efficiency surveys,” and “management studies”. This local guidance reinforces the necessity of the Shrinking Back Rule; by excluding “collateral” or “administrative” activities from the definition of R&D, the state essentially forces taxpayers to “shrink back” their analysis to the direct experimental work to meet the “direct and predominant use” requirement.

Application of the Shrinking Back Rule: A Step-by-Step Analysis

The application of the rule follows a logical downward progression, moving from the most complex business component to the most basic element. This process is essential for defending a claim during a New York State corporate tax audit.

Identification of the Discrete Business Component

The analysis must begin at the highest level—the level at which the product is held for sale or used in the business. For a software developer in New York City, this might be a comprehensive “FinTech Platform”.

Evaluation of the “Substantially All” Requirement

The taxpayer must determine if 80 percent of the costs associated with the FinTech Platform are experimental. If the platform development included $40\% routine API integration and database management, the overall platform fails the test.

Execution of the Shrink Back

The taxpayer identifies a subset of elements, such as a “Proprietary High-Frequency Trading Algorithm.” They apply the four-part test to this algorithm independently. If the algorithm meets the test, all costs associated with its development are qualified. If the algorithm itself fails (perhaps because it too included routine UI design), the taxpayer shrinks back further to the “Latency Optimization Module”.

Documentation of the Subset

The taxpayer must maintain contemporaneous records that link wages, supplies, and time to the specific subset of the business component. New York auditors will look for project descriptions that specify the technical unknowns associated with the “Latency Optimization Module” rather than the general business goals of the “FinTech Platform”.

Audit Evidence Required	Purpose in Shrinking Back	NY State Guideline Reference
Project Descriptions	Define the “shrunk back” component	TSB-M-11(6)I
Engineering Lab Notes	Prove a process of experimentation	TB-ST-773
Employee Time Logs	Allocate wages to the specific sub-component	CT-607 Instructions
Revision Histories	Document the evaluation of alternatives	ESD Performance Report
Prototype Records	Substantiate the elimination of uncertainty	QETC Guidelines

Judicial Precedents and Audit Risk Management

The interpretation of the Shrinking Back Rule has been significantly influenced by recent federal court cases, which are highly persuasive to New York tax authorities. The case of Little Sandy Coal v. Commissioner represents a landmark decision regarding the “substantially all” requirement. The court ruled that “substantially all” must be measured by the activities performed, not just by the final product. It held that if a taxpayer cannot provide detailed documentation showing that 80 percent of the activities involved experimentation, the credit must be disallowed at that level.

In Phoenix Design Group, Inc. v. Commissioner, the court acknowledged the existence of the Shrinking Back Rule but refused to apply it because the taxpayer failed to provide documentation at the sub-component level. The court noted that a taxpayer cannot carry its burden by merely presenting an eventual solution; they must show the investigative activities intended to eliminate uncertainty. For New York businesses, these cases highlight a critical risk: using the Shrinking Back Rule as an “after-the-fact” audit defense without having contemporaneous, component-level records is unlikely to succeed.

The “But For” Test and Economic Justification in New York

New York’s tax expenditure reports, such as those produced by PFM Group Consulting LLC, analyze whether tax incentives truly induce new research activity or merely reward what would have happened anyway. This “but-for” test is often reflected in audit procedures, where state examiners look for evidence that the credit influenced the technical direction of the company. By using the Shrinking Back Rule to isolate high-risk, high-uncertainty sub-components, companies can more effectively demonstrate that the credit was essential to overcoming specific technical hurdles that would otherwise have prevented the project’s success.

Sector-Specific Examples of the Shrinking Back Rule

To illustrate the rule’s utility, one must examine its application across New York’s diverse industrial landscape.

Manufacturing: The High-Performance Heat Exchanger

A manufacturer in Rochester is developing a new industrial heat exchanger. The overall project involves $\$500,000$ in total costs.

• Routine Work: $\$150,000$ for standard fabrication, assembly, and painting.
• Innovative Work: $\$350,000$ for developing a new internal fin geometry to increase thermal efficiency by $30\%$.

At the “Heat Exchanger” level, the innovative work is only $70\%$ of the total effort. Because $70\% < 80\%$, the project fails at the highest level. The manufacturer "shrinks back" to the "Fin Geometry Design." Within this sub-component, $100\%$ of the activity involved fluid dynamics modeling and iterative thermal testing. The manufacturer can now claim the $\$350,000$ as NY QREs, preserving the credit for the truly innovative portion of the work.

Software Development: The AI-Driven Analytics Tool

A software firm in the Silicon Alley district of Manhattan is building an analytics tool.

• Overall Component: The entire tool includes a standard user interface, a subscription management system, and a core AI engine.
• Analysis: The UI and subscription systems are routine. They represent $30\%$ of the total development time. The overall project fails the “substantially all” test.
• Shrink Back: The firm shrinks back to the “AI Predictive Engine.” This module requires novel machine learning models to identify patterns in unstructured data. The firm maintains time-logs specifically for the AI team. $90\%$ of the engine’s development was spent on evaluating different neural network architectures. This subset qualifies, and the firm claims the specific wages for the AI engineers.

Life Sciences: The New Biopharmaceutical Delivery System

A Buffalo-based biotech startup is developing a drug delivery patch.

• Overall Component: The patch includes the adhesive, the protective backing, and the micro-needle delivery array.
• Analysis: The adhesive and backing are sourced from existing medical-grade materials. The delivery array involves significant uncertainty regarding the rate of drug release and skin penetration.
• Shrink Back: The startup shrinks back to the “Micro-needle Array.” By isolating the wages of the biomedical engineers and the cost of the prototype materials for the needles, the startup meets the 80 percent threshold for that specific component, even if the overall patch development included routine regulatory and marketing tasks.

New York State Statistics and Economic Impact Analysis

The financial significance of these credits to the New York economy is substantial. According to the New York State Department of Taxation and Finance’s “Economic Impact of Tax Incentive Programs” report, the state’s economic development spending exceeds $\$11$ billion annually.

Metric	Value
Total Annual State Economic Development Cost	$\$11$ Billion
Excelsior Jobs Program Credits (2022)	$\$163$ Million
Life Sciences R&D Total Investments Leveraging Credits	$\$113$ Million
Average Life Sciences R&D Award	$\$244,000$
Green CHIPS Annual Credit Cap	$\$500$ Million
Statutory Statewide R&D Credit Allocation (Excelsior)	$\$10$ Million Rolling

Despite the high total spending, utilization for specific R&D programs like the Life Sciences credit remains concentrated in New York City, where 48 out of 57 awards were made in recent years. This geographic concentration suggests that the complexity of documentation and the “substantially all” requirement may be more easily navigated by firms with access to specialized tax and legal advisory services in the city.

Future Outlook: Legislative Changes and Section 174 Conformity

The landscape of R&D tax incentives is currently undergoing significant transformation due to federal legislative shifts. The Tax Cuts and Jobs Act (TCJA) of 2017 introduced the requirement to capitalize and amortize R&D expenses under Section 174 over five years for domestic research and fifteen years for foreign research.

New York, being a rolling conformity state for many corporate tax provisions, currently adheres to these capitalization requirements. This has created a “cash-tax” burden for many startups that previously used the R&D credit to offset immediate expenses. However, the proposed “One Big Beautiful Bill Act” (OBBBA) and other 2025 tax bill drafts aim to restore immediate expensing for domestic research costs.

If immediate expensing is restored, the value of the R&D tax credit will be amplified. Taxpayers will once again be able to pair a full deduction with a dollar-for-dollar credit. In this environment, the Shrinking Back Rule will become even more valuable, as it allows companies to maximize the “qualified” portion of their research spend, thereby maximizing both the deduction under Section 174A and the credit under Section 41.

Administrative Compliance and the ESD Certification Process

In New York, eligibility for the Excelsior and Life Sciences credits is not merely a matter of tax filing; it requires an upfront certification from Empire State Development. This process involves:

1. Consolidated Funding Application (CFA): The business must apply to the local ESD regional office, detailing its investment and job creation goals.
2. Certificate of Eligibility: Once approved, the business enters into an agreement with the state and receives a certificate of eligibility.
3. Performance Report: Within 30 days of the end of the taxable year, the business must submit a performance report demonstrating that it has satisfied the jobs and investment requirements.
4. Issuance of Tax Credit Certificate: Only after ESD verifies the performance report will it issue the final tax credit certificate required to claim the credit on a New York tax return (Forms CT-607 or CT-633).

The Shrinking Back Rule plays a role in the “Performance Report” phase. If a business falls short of its projected research intensity, it may use the shrink-back analysis to justify why a specific portion of its expenditures should still be considered “qualified” under the terms of the ESD agreement.

Final Thoughts

The Shrinking Back Rule is the primary defense against the disqualification of complex research projects that contain an unavoidable mix of routine and experimental activities. For New York businesses, the rule is not merely a federal curiosity but a fundamental component of state tax strategy, woven into the fabric of the Excelsior Jobs Program and the Life Sciences R&D Tax Credit. By allowing the taxpayer to refine the unit of analysis to the most innovative subsets of a project, the rule aligns tax policy with the realities of modern engineering, where breakthroughs are often iterative and modular.

However, the power of the Shrinking Back Rule is entirely dependent on the quality of contemporaneous documentation. As demonstrated by recent judicial rulings and the rigorous audit standards of the New York State Department of Taxation and Finance, taxpayers who fail to map their activities to discrete sub-components will find themselves unable to leverage this provision. For the high-tech, biotech, and manufacturing sectors that drive the New York economy, mastering the application of this rule is essential for securing the financial incentives that fuel the next generation of scientific and technological discovery. As legislative shifts continue to alter the landscape of Section 174 and Section 41, the Shrinking Back Rule will remain a constant, providing a necessary path to qualification for those who document their journey of innovation with precision and foresight.